Child growth and neurodevelopment after maternal antenatal antibiotic treatment

Karoliina Videman,1,2 Lotta Hallamaa,1 Otto Heimonen,1 Charles Mangani,3 Mari Luntamo,1 Kenneth Maleta,3 Per Ashorn,1,2 Ulla Ashorn1

ABSTRACT

Objective To assess whether intermittent preventive treatment of pregnant women (IPTp) with sulfadoxine-pyrimethamine (SP) and azithromycin (AZI) in a malaria-endemic area leads to sustained gains in linear growth and development in their offspring.

Design Follow-up study of a randomised trial.

Setting Mangochi District in rural southern Malawi.

Participants 1320 pregnant women and their offspring.

Interventions IPTp monthly with SP and twice with AZI (AZI-SP group), monthly with SP but no AZI (monthly SP), or twice with SP (control). No intervention was given to children.

Main outcome measures Cognitive performance using Raven’s Coloured Progressive Matrices (CPM) at 13 years of age; mean height and height-for-age Z-score (HAZ), cumulative incidence and prevalence of stunting (HAZ < −2); weight, body mass index, mid-upper-arm circumference and head circumference.

Results At approximately 13 years of age, the mean CPM score was 14.3 (SD 3.8, range 6–29, maximum 36), with no differences between groups. Children in the AZI-SP group were on average 0.4 cm (95% CI −0.9 to 1.7, p=0.8) taller than those in the control group. For cumulative incidence of stunting, the HR in the AZI-SP group was 0.72 (95% CI 0.61 to 0.84, p<0.001) compared with the control and 0.76 (95% CI 0.65 to 0.90, p<0.001) compared with the monthly SP groups. There was no intergroup difference in stunting prevalence or anthropometric measurements.

Conclusions In rural Malawi, maternal intensified infection control during pregnancy reduces offspring’s cumulative incidence of ever being stunted by 13 years of age. In this study, there was no evidence of a positive impact on cognitive performance.

Trial registration number NCT00131235.

INTRODUCTION

Globally, 21% of children under 5 years old are estimated to be stunted, most of them living in low-income and middle-income countries. There is robust evidence that better linear growth during the first 2 years of life is positively associated with cognitive and motor development. As brain development begins in the third week of gestation and some 75% of brain growth occurs during the first 1000 days, the antenatal period is crucial for promotion of brain development. Stunting often has its origins in the fetal period, resulting in fetal growth restriction (FGR) and subsequent growth faltering in the first 2 years of life. Nutritional interventions during pregnancy seem to modestly increase mean birth length and weight but these gains are typically lost in infancy. Intermittent preventive treatment of pregnant women (IPTp) with sulfadoxine-pyrimethamine (SP) compared with SP twice during pregnancy increases birth weight, but birth length data have rarely been reported. There is evidence that adding maternal azithromycin (AZI) treatment during pregnancy reduces the prevalence of preterm birth and fetal and neonatal growth faltering in malaria-endemic areas. The impact of these interventions on child development remains unclear.

In a trial in Malawi, we showed that intensified antenatal infection control can reduce stunting in infancy and early childhood and improve cognitive development by 5 years of age. The intervention may also have reduced postneonatal mortality. We now describe the follow-up results from this trial, aimed to assess the sustainability of the gains in cognitive capacity and growth by early adolescence. As later childhood developmental status is known to be affected by not only genetics and
the first 1000 days period, but also childhood exposures, we wanted to assess any possible differences at approximately 13 years of age. The main question was if children of mothers who received intensified infection control during pregnancy would (1) still have better cognitive performance, (2) have a lower cumulative incidence of stunting and (3) be taller in preadolescence than children whose mothers received standard care.

METHODS

Background

The study was a 13-year follow-up to the Lungwena Antenatal Intervention Study (LAIS), a randomised, partially placebo-controlled, outcome assessor-blinded, three-arm clinical trial from rural southern Malawi. The original trial showed that preterm delivery and low birth weight were lower and infant size at 1 month was bigger with intensive infection treatment during pregnancy. A follow-up at 5 years indicated that the intervention also reduced the incidence of stunting and had a positive effect on child development.

Participants and follow-up

The LAIS enrolled women with uncomplicated second trimester pregnancies at 14–26 weeks gestation by ultrasound assessment who felt fetal movements. Exclusion criteria included severe illness, receipt of AZI during the current pregnancy or SP within the preceding 28 days, allergy to study drugs, and any previous serious allergic reaction.

Participants in the control group received standard Malawian antenatal care, which at the time of the study included IPTp with SP (1500 mg of sulfadoxine and 75 mg of pyrimethamine) twice: at enrolment and between 28 and 34 weeks of gestation. They also received a placebo to AZI. Participants in the monthly SP intervention group received SP monthly from enrolment until 37 gestational weeks and a placebo to AZI as the control group. Participants in the AZI-SP intervention group received monthly SP and active AZI (1000 mg) at enrolment and between 28 and 34 weeks of gestation. No intervention was given to the offspring. Additional detailed methods are provided in the online supplemental information.

The current follow-up was planned as a separate entity and implemented between December 2017 and March 2019. The study team made visits to the homes of children who had participated in the original LAIS trial and were not known to have died. If the participants had moved, the study team attempted to find information on their new location from nearby households. Each participant and at least one of caregiver provided a new informed consent before participation.

We included all children in the analyses except for those with missing data for the specific outcome. Originally, we planned to evaluate the participants at prepubertal phase at approximately 12 years of age. However, due to delays in implementation, the data were collected later than planned, which resulted in a higher mean age and a larger age range. We accounted for age variation by adjusting the analyses for age and pubertal stage.

Outcomes

Child development was assessed by the Raven’s Coloured Progressive Matrices (CPM), which measures non-verbal intelligence and can be used among illiterate people. The reliability and criterion validity have been found good in Africa. The test comprises 36 items; each correct answer provides a score of 1 and each incorrect or no answer is counted as 0. Two research assistants administered the Raven’s test at the study clinic.

Child anthropometry was assessed by two anthropometrists, in triplicate. For the analysis, we used the mean of the first two readings if they did not differ by more than 0.1 kg for weight or 0.5 cm for other measurements. If the tolerance limit was exceeded, we calculated the mean from the pair of two measurements closest to each other.

Primary follow-up outcomes were CPM score, child height, weight, body mass index (BMI), mid-upper-arm circumference (MUAC) and head circumference (HC) at approximately 13 years of age. For attained length and acute nutritional status, we also calculated the prevalence of stunting and severe stunting (≤−2 and ≤−3 height-for-age Z-scores, HAZ) and low and very low BMI (≤−2 SD and ≤−3 BMI Z-scores, BMIZ). These dichotomous outcomes were based on age-standardised and sex-standardised HAZ and BMIZ, using the WHO 2007 child growth standard (age ≥61 months). For the change in Z-scores, we used HAZ and BMIZ values at 5 years, calculated based on the WHO multicentre growth standard for <61 months old. The growth measurements were adjusted for socioeconomic status (SES) and pubertal stage, assessed by a study nurse using Tanner classification.

Statistical analysis

A sample size of 440 pregnant women per group was planned to give 80% power at a 5% level of significance to detect a 40% reduction in the rate of preterm delivery, which was the trial’s main hypothesis. Intention-to-treat analyses were used.

For CPM score, absolute height, weight, BMI, MUAC and HC, we calculated the means and the difference between the three groups was tested with least square regression. For prevalence of stunting, severe stunting, low BMI and very low BMI, we calculated percentages and used a log-binomial regression model to estimate risk ratios. To prevent inflated type I errors due to testing between multiple groups, we began hypothesis testing with a global null hypothesis of no difference between any groups using Wald’s test. Null hypotheses were rejected if p<0.05. Pairwise null hypotheses were rejected only if the global null hypothesis was also rejected. We included age, sex, pubertal stage and SES as covariates in the statistical analyses. SES was expressed as a score that was established with principal component analysis by combining information on the building material of the house, main source of water, type of sanitary facility available and ownership of household items.

RESULTS

Of the 3358 approached pregnant women, 1320 (39.3%) were enrolled and randomly assigned to the control (436), monthly SP (441) and AZI-SP (443) groups. In the current analysis, we had data for 997 (75.1%) children on development and for 1002 (75.5%) on anthropometrics. Success of follow-up was similar between the groups (figure 1).

At enrolment, the intervention groups were similar except for small differences in maternal malaria prevalence and number of previous pregnancies. Mothers who were lost to follow-up were similar to those who stayed in the study except for HIV prevalence (11% vs 22%, p<0.001) (online supplemental table 1). Pubertal status and years of schooling of the offspring at follow-up were similar between the groups (table 1).

At the follow-up visit, the mean age of the participants was 12.8 (SD 0.9, range 10.9–14.6) years. Their CPM scores ranged between 6 and 29 (online supplemental figure 1). There were no statistically significant differences between the groups (table 2).
The participants’ mean height (HAZ) was 52 cm (−1.3) at 1 month, 81 cm (−2.1) at 2 years, 102 cm (−1.7) at 5 years and 143 cm (−1.7) at 12.8 years (online supplemental figure 2). At the last follow-up, children in the AZI-SP group were on average 0.4 cm (95% CI −0.9 to 1.7) taller than children in the control group (table 2). In absolute length, the point estimate for the intergroup difference was similar to the difference observed at earlier time points, but was statistically significant only at 24 months old or younger (figure 2).

The cumulative incidence of ever being stunted was 79%, 77% and 67% in the control, SP and AZI-SP groups and for severe stunting 42%, 39% and 29%, respectively. The HR (95% CI) for being stunted at least once was 0.72 (0.61 to 0.84, p<0.001) in the AZI-SP group compared with the control group.

### Table 1 Baseline characteristics of the participating women at enrolment and their offspring at 13 years, by study group

<table>
<thead>
<tr>
<th>Maternal characteristics</th>
<th>Control (SP twice) (n=436)</th>
<th>Monthly SP (n=441)</th>
<th>AZI-SP (n=443)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years, mean (SD)</td>
<td>25 (7)</td>
<td>25 (7)</td>
<td>25 (6)</td>
</tr>
<tr>
<td>Gestational age at enrolment, weeks, mean (SD)</td>
<td>20.3 (3.0)</td>
<td>20.0 (3.2)</td>
<td>20.0 (3.0)</td>
</tr>
<tr>
<td>Primiparous (%)</td>
<td>110 (25.2)</td>
<td>107 (24.3)</td>
<td>89 (20.1)</td>
</tr>
<tr>
<td>HIV-positive (%)</td>
<td>48/396 (12.1)</td>
<td>64/400 (16.0)</td>
<td>49/398 (12.3)</td>
</tr>
<tr>
<td>Microscopic peripheral blood malaria parasitaemia (%)</td>
<td>49/435 (11.3)</td>
<td>41 (9.3)</td>
<td>27 (6.1)</td>
</tr>
<tr>
<td>Blood Hb concentration, g/L, mean (SD)</td>
<td>110 (19)</td>
<td>111 (17)</td>
<td>110 (20)</td>
</tr>
<tr>
<td>Moderate or severe anaemia, Hb &lt;100 g/L (%)</td>
<td>116 (26.6)</td>
<td>106 (24.0)</td>
<td>129 (29.1)</td>
</tr>
<tr>
<td>Literate participants (%)</td>
<td>116 (26.6)</td>
<td>129 (29.3)</td>
<td>139 (31.4)</td>
</tr>
<tr>
<td>Years of schooling completed, mean (SD)</td>
<td>2.1 (2.7)*</td>
<td>2.2 (2.6)</td>
<td>2.4 (2.8)</td>
</tr>
<tr>
<td>Offspring characteristics at 13 years of age</td>
<td>n=333</td>
<td>n=333</td>
<td>n=337</td>
</tr>
<tr>
<td>Years of schooling completed</td>
<td>0 (%)</td>
<td>48 (14.4)</td>
<td>62 (18.6)</td>
</tr>
<tr>
<td>1–3 (%)</td>
<td>186 (55.9)</td>
<td>168 (50.5)</td>
<td>163 (48.4)</td>
</tr>
<tr>
<td>&gt;3 (%)</td>
<td>99 (29.7)</td>
<td>103 (31.0)</td>
<td>121 (36.0)</td>
</tr>
<tr>
<td>Pubertal stage</td>
<td>n=332</td>
<td>n=330</td>
<td>n=333</td>
</tr>
<tr>
<td>Stage 1 (%)</td>
<td>162 (48.8)</td>
<td>175 (53.0)</td>
<td>155 (46.6)</td>
</tr>
<tr>
<td>Stage 2 (%)</td>
<td>100 (30.3)</td>
<td>88 (26.7)</td>
<td>101 (30.1)</td>
</tr>
<tr>
<td>Stages 3–5 (%)</td>
<td>70 (21.1)</td>
<td>67 (20.3)</td>
<td>77 (23.1)</td>
</tr>
</tbody>
</table>

*Value missing for one participant.

AZI-SP, intervention group with monthly SP and two doses of azithromycin; Hb, haemoglobin; SP, sulfadoxine-pyrimethamine.
and 0.76 (0.65 to 0.90, p=0.001) compared with the monthly SP group. The HR among children in the AZI-SP group for ever developing severe stunting was 0.65 (0.51 to 0.82, p<0.001) and 0.69 (0.54 to 0.88, p=0.002) compared with the control and monthly SP groups, respectively (figure 3). The intergroup differences were slightly larger among girls than boys (online supplemental figure 3).

At 12.8 years, the mean (SD) weight of the study participants was 33.9 (6.6) kg, BMI 16.5 (1.8) kg/m², MUAC 19.9 (2.1) cm and HC 51.6 (1.5) cm. There were no significant differences between the groups (table 2). There were also no intergroup differences in most sex-specific analyses (online supplemental tables 2 and 3), except for HC among girls, which were 51.2 cm, 51.0 cm and 51.6 cm in the control, monthly SP and AZI-SP groups, respectively (p=0.006).

The prevalence of stunting at 12.8 years was 36%, 39% and 36% and that of severe stunting 7.5%, 8.7% and 6.0% in the control, monthly SP and AZI-SP groups, respectively (global p values 0.6 and 0.4 for stunting and severe stunting). The prevalence of stunting and severe stunting was highest at 24 months, whereas it remained stable from 5 to 12.8 years (online supplemental figure 4). The prevalence of low and very low BMI was 12% and 1.6%, with no statistically significant differences between the groups (p=0.2 for low and p=0.06 for very low BMI) (online supplemental table 4).

**DISCUSSION**

Our aim was to test if intensified preventive maternal antenatal infection control would lead to growth and developmental benefits in their offspring still evident in preadolescence. In a sample of 997 Malawian children aged 11–15 years old, there was no difference in mean CPM scores in the different intervention groups. Children whose mothers had received monthly SP and two doses of AZI during pregnancy were on average 4 mm taller and their cumulative incidence of ever being stunted was 13% lower than children whose mothers had been treated only with two doses of SP. However, at 11–15 years of age, there was no difference in the prevalence of stunting between the groups.

The validity of our findings could have been compromised by imbalanced group allocation, differential loss to follow-up, missing data, measurement bias and random error in statistical inference. However, the groups were randomly allocated and well balanced at baseline and the proportion of participants lost to follow-up was similar between the groups. The baseline characteristics of those lost to follow-up were similar to those remaining in the study. Maternal HIV infection was associated with loss to follow-up but did not modify the association between the intervention and the studied outcomes (data not shown). The difference in mean height between the groups was not statistically significant in preadolescence, but the point estimate was identical observed when the children were younger. Furthermore, the difference in cumulative stunting incidence was statistically significant. Thus, the sample findings are consistent with a hypothesis that intensified preventive maternal infection treatment during pregnancy leads to a modest impact on the cumulative incidence of stunting, sustained until preadolescence. In contrast, the findings do not support a sustained impact on child development.

Although several earlier trials have studied the impact of maternal antenatal infection control interventions on birth size,10–12 there are no publications on the impact of these interventions on subsequent child growth. For child development, there are data from the ORACLE trial (antibiotics for preterm, prelabour rupture of membranes and preterm labour) from England, in which women experiencing either preterm premature rupture of membranes (PPROM) or spontaneous preterm labour (SPL) were prescribed either erythromycin, amoxycillin-clavulanate, both, or neither. This study suggested a small benefit of erythromycin treatment in newborn survival among women with PPROM. The 7-year follow-up results of the offspring raised concerns about an increased risk of functional impairment in the group that received erythromycin for SPL, and an increased risk for cerebral palsy (CP) with any antibiotic treatment.27 28 In a follow-up study carried out at 11 years of age, there was neither harm nor benefit on educational attainment in any group.29 The

---

**Table 2** Mean developmental outcome, height, weight, BMI, MUAC and HC in preadolescence, by intervention group

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Control (SP twice) (n=333) Mean (SD)</th>
<th>Monthly SP (n=333) Mean (SD)</th>
<th>AZI-SP (n=336) Mean (SD)</th>
<th>Global p value</th>
<th>Global p value, adjusted*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raven’s score†</td>
<td>14.2 (3.7)</td>
<td>14.4 (3.8)</td>
<td>14.2 (3.9)</td>
<td>0.8</td>
<td>0.8</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>142.7 (8.1)</td>
<td>142.5 (8.2)</td>
<td>143.1 (8.4)</td>
<td>0.6</td>
<td>0.7</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>33.8 (6.3)</td>
<td>33.8 (6.9)</td>
<td>34.2 (6.5)</td>
<td>0.6</td>
<td>&gt;0.9</td>
</tr>
<tr>
<td>BMI</td>
<td>16.4 (1.7)</td>
<td>16.5 (2.1)</td>
<td>16.5 (1.6)</td>
<td>0.7</td>
<td>0.9</td>
</tr>
<tr>
<td>MUAC (cm)</td>
<td>19.9 (2.1)</td>
<td>19.8 (2.3)</td>
<td>20.0 (2.0)</td>
<td>0.2</td>
<td>0.5</td>
</tr>
<tr>
<td>HC (cm)</td>
<td>51.6 (1.4)</td>
<td>51.5 (1.6)</td>
<td>51.8 (1.5)</td>
<td>0.1</td>
<td>0.08</td>
</tr>
</tbody>
</table>

*Adjusted for child sex, age, socioeconomic status and pubertal stage at the time of developmental assessment and anthropometric measurements.

†For the Raven's score n=331, n=332 and n=334.
than babi

growth in the offspring. Infection control during pregnancy could also support healthy outcomes. Studies often lost postnatally are often on their overall stature, which can be measured by height-for-age Z-scores (HAZ).36

The antenatal intervention of repeated doses of antibiotics, such as azithromycin (AZI), was evaluated in a study by Videman et al.2021. The intervention was given to pregnant women to assess its impact on child development through childhood. The authors concluded that the intervention could be a potential tool for improving child development, especially in low-income settings.

Timing of treatment and antibiotic sub-type were different in our trial, but both studies suggest that any impact of maternal antenatal macrolide treatment on child development would have waned by mid-childhood.

The most common approach tried to increase birth size is maternal dietary supplementation. Several interventions have been shown to have a positive impact on infant weight and in some studies on length at birth, especially among babies of malnourished women.30 However, only a few studies have assessed the persistence of gains in birth size through childhood. In the multicountry Women First trial, babies born to women who had been given lipid-based nutrient supplements during pregnancy were on average 3–4 mm taller and 60 g heavier than babies born to women who received no supplement, and the difference persisted for at least 6 months.31 Similarly, antenatal dietary supplementation resulted in linear growth benefits that were reflected in lower stunting prevalence until 5 years of age in two Asian studies.32 33 Our results suggest that maternal antenatal infection control during pregnancy could also support healthy growth in the offspring.

In contrast to intrauterine gains in weight-for-length, which are often lost postnatally,7-9 intrauterine gains in length seem to be more sustainable. Weight-for-length follows the child’s postnatal nutritional status, whereas accrued bone length will not be reduced even in subsequent adverse growth conditions. Intergroup differences in newborn length can, however, disappear if the taller group has a higher mean gestational age at birth because postnatal length gain velocity is inversely associated with duration of pregnancy.29 The statistical significance of a given absolute difference in length will also wane over time due to the increasing population variance in length.34

Fetal length gain is regulated by insulin-like growth factors (IGFs), secreted by maternal tissues, the placenta and the fetus on various stimuli.33 Systemic inflammation, elicited by maternal or placental infection, downregulates the expression of IGFs and their cellular receptors, reduces placental nutrient transfer, and thus causes FGR.28 The antenatal intervention of repeated doses of SP and AZI probably promoted fetal growth by reducing systemic inflammation caused by maternal malaria and other infections.11 Alleviation of inflammation-induced hypomyelination of fetal brain, leading to better neural connectivity, is a possible mechanism of how the intervention had a positive impact on early child development.14 15 37 The impact may have subsequently waned because by mid-childhood cognitive development is greatly affected by external factors such as schooling, play sessions and other stimulation. Beyond the first 1000 days, neurocognitive development is a result of early childhood and mid-childhood exposures: disease prevention, nutrition, security and safety, caregiving practices, and early learning possibilities.4 16 38 39

One limitation of our study is the method used for assessing cognitive development. At 5 years of age, we used the Griffith’s Mental Developmental Scales, which provides a score for five different developmental domains. With this test, better developmental performance in the AZI-SP group was mainly observed in the ‘performance’ domain, measuring visuospatial skills such as speed of work and precision.41 There is no universally approved instrument for measuring cognitive function among preadolescents in low-income settings.41 We used CPM, which is viewed as a culturally robust tool for measuring logical reasoning.19 The Raven’s test resembles the ‘performance’ domain of the Griffith’s test. The normal distribution of Raven’s scores in our sample is reassuring that the test captured appropriately one dimension of child development. However, the mean score was lower than earlier reported from similar-aged children in high-income settings.19 This could be attributed to the complexity of child development.16 39 It is possible that we might have missed a subtle intervention impact on one or more developmental domains.

In conclusion, these findings do not support the hypothesis of long-lasting positive effects of antenatally administered intensive infection control on neurocognitive development. However, the intervention seems to decrease the cumulative incidence of ever being stunted in childhood.

**Acknowledgements** We thank the study participants and the study staff. Azithromycin and its placebo were provided free of charge by Pfizer (New York, New York, USA), Nutricia (Amsterdam, Netherlands) and Nestle (Vevey, Switzerland). We thank the study participants and the study staff. Azithromycin and its placebo were provided free of charge by Pfizer (New York, New York, USA).
Supplemental material

This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD

Karolina Videman http://orcid.org/0000-0002-8367-4451

REFERENCES

Supplemental information

Methods

Participants and Follow-up

A researcher not involved in data collection generated a randomised code list blocks of 9 that allocated women enrolled to the study to either control group or 1 of 2 intervention groups. On the basis of this list, individual code slips containing unique identification numbers, but not group allocation, were sealed in individual opaque randomisation envelopes. Eligible persons who consented to participate picked 1 envelope that contained an identification number. A research assistant not involved in outcome assessment gave the corresponding prepacked study drugs to the participant under direct observation and monitored her for possible adverse reactions. Research personnel assessing child anthropometrics and development were blinded to the intervention group throughout the follow-up.

All participants were given ferrous sulfate (200 mg/day) and folic acid (0.25 mg/day) throughout pregnancy. All children received standard Malawian care during follow-up; HIV-positive mothers and their newborns received nevirapine for prevention of mother-to-child transmission of HIV.

None of the deaths were judged to be due to the maternal intervention. Other types of neonatal severe adverse events (SAEs) were evenly distributed between the groups. Most SAEs were not considered related to trial interventions.

The study was performed according to Good Clinical Practice and the ethical standards of the Declaration of Helsinki. The protocol was approved by the College of Medicine Research and Ethics Committee (COMREC), Malawi, and the Ethical Committee of Pirkanmaa Hospital District, Finland.
Outcomes

At 5 years of age the cognitive development was tested using Griffith’s Mental Development Scales, Extended Revised, 2-8 years (GMDS-ER 2-8), which covers 6 domains: locomotor, personal-social, language, eye and hand coordination, performance and practical reasoning.

References

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Follow-up (n=1002)</th>
<th>Lost to follow-up (n=318)</th>
<th>Difference (95%CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years, mean (SD)</td>
<td>24.9 (6.4)</td>
<td>24.7 (6.4)</td>
<td>-0.13 (-0.94 to 0.68)</td>
<td>0.8</td>
</tr>
<tr>
<td>Gestational age at enrollment, weeks, mean (SD)</td>
<td>20.1 (3.1)</td>
<td>20.0 (2.9)</td>
<td>-0.16 (-0.54 to 0.23)</td>
<td>0.4</td>
</tr>
<tr>
<td>Proportion of primiparity</td>
<td>24 %</td>
<td>23 %</td>
<td>-0.01 (-0.06 to 0.04)</td>
<td>0.7</td>
</tr>
<tr>
<td>Proportion of HIV-positive participants (N = 908)</td>
<td>11 %</td>
<td>22 % (N =291)</td>
<td>0.11 (0.06 to 0.16)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Proportion of literate participants (%)</td>
<td>29 %</td>
<td>29 %</td>
<td>-0.01 (-0.06 to 0.05)</td>
<td>0.8</td>
</tr>
<tr>
<td>Proportion of moderate or severe anemia, Hb &lt;100g/L (%)</td>
<td>26 %</td>
<td>29 %</td>
<td>0.03 (-0.03 to 0.08)</td>
<td>0.3</td>
</tr>
<tr>
<td>Years of schooling completed, mean (SD)</td>
<td>2.2 (2.7)</td>
<td>2.3 (2.7)</td>
<td>0.02 (-0.32 to 0.36)</td>
<td>&gt;0.9</td>
</tr>
</tbody>
</table>
**Supplemental table 2.** Mean developmental outcome, height, weight, body mass index (BMI), mid-upper arm circumference (MUAC) and head circumference (HC) of boys in preadolescence, by intervention group

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Control (SP twice) (N=161). Mean (SD)</th>
<th>Monthly SP (N=182). Mean (SD)</th>
<th>AZI-SP (N=161). Mean (SD)</th>
<th>Global p-value</th>
<th>Global p-value, adjusted&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raven’s score&lt;sup&gt;a&lt;/sup&gt;</td>
<td>14.4 (4.1)</td>
<td>14.6 (4.0)</td>
<td>14.7 (4.2)</td>
<td>&gt;0.9</td>
<td>0.8</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>140.3 (7.8)</td>
<td>141.4 (7.9)</td>
<td>140.7 (8.1)</td>
<td>0.4</td>
<td>&gt;0.9</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>31.9 (5.3)</td>
<td>32.5 (5.7)</td>
<td>32.3 (5.3)</td>
<td>0.6</td>
<td>0.9</td>
</tr>
<tr>
<td>BMI</td>
<td>16.1 (1.4)</td>
<td>16.2 (1.5)</td>
<td>16.2 (1.2)</td>
<td>0.2</td>
<td>0.8</td>
</tr>
<tr>
<td>MUAC (cm)</td>
<td>18.9 (1.6)</td>
<td>19.0 (1.7)</td>
<td>19.3 (1.6)</td>
<td>0.2</td>
<td>0.08</td>
</tr>
<tr>
<td>HC (cm)</td>
<td>52.0 (1.5)</td>
<td>52.0 (1.5)</td>
<td>52.0 (1.4)</td>
<td>&gt;0.9</td>
<td>0.6</td>
</tr>
</tbody>
</table>

<sup>a</sup> For the Raven’s score N=160, 181 and 160.

<sup>b</sup> Adjusted for child age, socioeconomic status and pubertal stage at the time of developmental assessment and anthropometric measurements.

SP = sulfadoxine-pyrimethamine. AZI-SP = intervention group with monthly SP and two doses of azithromycin.
Supplemental table 3. Mean developmental outcome, height, weight, body mass index (BMI), mid-upper arm circumference (MUAC) and head circumference (HC) of girls in preadolescence, by intervention group

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Control (SP twice) (N=172). Mean (SD)</th>
<th>Monthly SP (N=151). Mean (SD)</th>
<th>AZI-SP (N=175). Mean (SD)</th>
<th>Global p-value</th>
<th>Global p-value, adjusted&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raven’s score&lt;sup&gt;a&lt;/sup&gt;</td>
<td>13.6 (3.1)</td>
<td>14.0 (3.4)</td>
<td>13.8 (3.5)</td>
<td>0.5</td>
<td>0.2</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>145.0 (7.8)</td>
<td>143.8 (8.4)</td>
<td>145.3 (8.1)</td>
<td>0.3</td>
<td>0.3</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>35.5 (6.7)</td>
<td>35.3 (8.0)</td>
<td>36.0 (7.0)</td>
<td>0.6</td>
<td>0.9</td>
</tr>
<tr>
<td>BMI</td>
<td>16.8 (2.0)</td>
<td>16.9 (2.6)</td>
<td>16.9 (1.9)</td>
<td>0.8</td>
<td>0.6</td>
</tr>
<tr>
<td>MUAC (cm)</td>
<td>20.7 (2.1)</td>
<td>20.7 (2.6)</td>
<td>20.8 (2.1)</td>
<td>&gt;0.9</td>
<td>&gt;0.9</td>
</tr>
<tr>
<td>HC (cm)</td>
<td>51.2 (1.3)</td>
<td>51.0 (1.5)</td>
<td>51.6 (1.6)</td>
<td>0.006</td>
<td>0.009</td>
</tr>
</tbody>
</table>

<sup>a</sup> For the Raven’s score N=171, 151 and 174.

<sup>b</sup> Adjusted for child age, socioeconomic status and pubertal stage at the time of developmental assessment and anthropometric measurements.

SP = sulfadoxine-pyrimethamine. AZI-SP = intervention group with monthly SP and two doses of azithromycin.
**Supplemental table 4.** Prevalence of stunting, severe stunting, low BMI and very low BMI in preadolescence, by intervention group

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Control (SP twice), N=333 (n)</th>
<th>Monthly SP, N=333 (n)</th>
<th>AZI-SP, N=336 (n)</th>
<th>Global p-value</th>
<th>Global p-value, adjusted(^a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stunting, HAZ &lt;-2SD</td>
<td>36.0 % (120)</td>
<td>39.0 % (130)</td>
<td>36.0 % (121)</td>
<td>0.6</td>
<td>0.9</td>
</tr>
<tr>
<td>Severe stunting, HAZ &lt;-3SD</td>
<td>7.5 % (25)</td>
<td>8.7 % (29)</td>
<td>6.0 % (20)</td>
<td>0.4</td>
<td>0.7</td>
</tr>
<tr>
<td>Low BMI, (BMIZ&lt;-2)</td>
<td>13.2 % (44)</td>
<td>13.5 % (45)</td>
<td>9.2 % (31)</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>Very low BMI, (BMIZ&lt;-3)</td>
<td>1.5 % (5)</td>
<td>3.0 % (10)</td>
<td>0.3 % (1)</td>
<td>0.06</td>
<td>0.09</td>
</tr>
</tbody>
</table>

\(^a\) Adjusted for child’s pubertal stage and socioeconomic status at the time of anthropometric measurements.

SP = sulfadoxine-pyrimethamine. AZI-SP = intervention group with monthly SP and two doses of azithromycin.
**Supplemental figure 1.** Distribution of Raven’s coloured progressive matrices (CPM) score, all groups combined.
**Supplemental figure 2.** Development of mean height and length-for-age Z-score (LAZ)/height-for-age Z-score (HAZ), at one and 6 months, 1, 2, 3, 4, 5 and approximately 12 years of age, all groups combined. Error bars indicate standard deviation (SD).
**Supplemental figure 3.** Cumulative incidence of stunting (HAZ < -2SD) and severe stunting (HAZ < -3SD) of boys and girls from one month to approximately 13 years of age by intervention group.

SP = sulfadoxine-pyrimethamine, AZI-SP = intervention group with monthly SP and two doses of azithromycin, HR = hazard ratio, CI = confidence interval.
**Supplemental figure 4.** Prevalence of stunting (HAZ < -2SD) and severe stunting (HAZ < -3SD) with 95% confidence intervals from one month to approximately 12 years of age by intervention group. Stunting (HAZ < -2, upper sets of lines) and severe stunting (HAZ < -3, lower sets of lines) are shown.

SP = sulfadoxine-pyrimethamine, AZI-SP = intervention group with monthly SP and two doses of azithromycin.